UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 15, 2005
LIFELINE
THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Colorado |
000-30489 |
84-1097796 | |||
|---|---|---|---|---|---|
| (State or other jurisdiction | (Commission File Number) | (IRS Employer Identification No.) | |||
| of incorporation) | |||||
6400 South
Fiddler’s Green Circle, Suite 1970, Englewood, CO 80111
(Address of principal
executive offices) (Zip Code)
Registrant’s telephone number, including area code: (720) 488-1711
N/A
(Former
name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure.
On November 15, 2005, Lifeline Therapeutics, Inc. issued a press release entitled “Lifeline Therapeutics Announces First Quarter Results.” The press release is attached as Exhibit 99.1 hereto.
ITEM 9.01 Financial Statements and Exhibits.
Exhibit
99.1 Lifeline Therapeutics Announces First Quarter Results |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 17, 2005
LIFELINE
THERAPEUTICS, INC. |
2
Media
Contact:
Amy Cone Burrell
720-488-1711
LIFELINE THERAPEUTICS ANNOUNCES FIRST QUARTER RESULTS
ENGLEWOOD, COLORADO, November 15, 2005 — Lifeline Therapeutics, Inc. (OTCBB:LFLT) today announced results for its first quarter ended September 30, 2005. Sales revenue for the quarter was $2,964,591 as compared with no sales revenue for the same quarter in the prior fiscal year. Lifeline launched sales of its product, Protandim®, during the second half of the fiscal year ended June 30, 2005, and the Company had no sales revenue prior to that time.
Lifeline had a net income of $80,315 for the first quarter of the fiscal year, which included $2,296,253 in operating expenses, in addition to $596,561 for cost of sales. For the fiscal quarter ended September 30, 2004, Lifeline had a net loss of $331,229, which included total operating expenses of $267,336.
“We are pleased with our first quarter sales of Protandim, for which our product launch occurred in February of 2005,” stated interim CEO Brenda March. “We also believe we have strengthened our financial position significantly with the conversion and repayment of our interest-bearing debt that occurred before the end of our June 30, 2005 fiscal year. Additionally, we plan to complete our search and hire a new CEO within the next 30 days.”
ABOUT LIFELINE THERAPEUTICS
Lifeline Therapeutics, Inc. is a publicly-traded company (OTCBB: LFLT) based in Denver, Colorado that markets Protandim, a patent-pending dietary supplement that increases the body’s natural antioxidant protection. For more information, please visit the company website at www.lifelinetherapeutics.com or the Protandim product website at www.protandim.com.
###
Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company’s control. Other important factors that the Company believes might cause such differences include the Company’s limited cash flow and the rapid development of technology, lack of liquidity for the Company’s common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company’s filings with the Securities and Exchange Commission.